127 related articles for article (PubMed ID: 20737543)
1. Incidence of Parkinson's disease among hospital patients with methamphetamine-use disorders.
Callaghan RC; Cunningham JK; Sajeev G; Kish SJ
Mov Disord; 2010 Oct; 25(14):2333-9. PubMed ID: 20737543
[TBL] [Abstract][Full Text] [Related]
2. Increasing incidence of Parkinson's disease in patients with epilepsy: A Nationwide cohort study.
Hwang YS; Kang MG; Yeom SW; Jeong CY; Shin BS; Koh J; Kim JS; Kang HG
J Neurol Sci; 2024 Mar; 458():122891. PubMed ID: 38310734
[TBL] [Abstract][Full Text] [Related]
3. Increased Risk of New-Onset Parkinson's Disease Following a Diagnosis of Retinal Vascular Occlusion: A 14-Year Cohort Study.
Kim SH; Park M; Jeong SH
J Gerontol A Biol Sci Med Sci; 2024 May; 79(5):. PubMed ID: 38469740
[TBL] [Abstract][Full Text] [Related]
4. Early onset Parkinson's disease in the cycle of 3,4-methylenedioxymethamphetamine and substance use: a case report.
Hui T; Guo S
J Med Case Rep; 2023 Sep; 17(1):405. PubMed ID: 37740189
[TBL] [Abstract][Full Text] [Related]
5. No Associations Between Glucosamine Supplementation and Dementia or Parkinson's Disease: Findings From a Large Prospective Cohort Study.
Ai B; Chen L; Cai M; Fu J; Li H; Lin H; Zhang Z
J Gerontol A Biol Sci Med Sci; 2024 Feb; 79(2):. PubMed ID: 37158699
[TBL] [Abstract][Full Text] [Related]
6. Modelling the trends of inpatient and outpatient rehabilitation for methamphetamine in the Western Cape province of South Africa.
Mushanyu J; Nyabadza F; Stewart AG
BMC Res Notes; 2015 Dec; 8():797. PubMed ID: 26681295
[TBL] [Abstract][Full Text] [Related]
7. [Clinical profile and non-recreational methamphetamine abuse (shabu) among stroke patients in the Philippine population].
Rodríguez-Campello A; Figueras-Aguirre G; Puchades V; Ois-Santiago A; Cuadrado-Godia E; Giralt-Steinhauer E; Jiménez-Conde J; Bertran-Recasens B; Fernández-Pérez I; Soriano-Tárraga C; Mateus JA; Roquer J
Rev Neurol; 2023 Dec; 77(12):293-298. PubMed ID: 38095053
[TBL] [Abstract][Full Text] [Related]
8. Methamphetamine use association with pulmonary diseases: a retrospective investigation of hospital discharges in California from 2005 to 2011.
Tsai H; Lee J; Hedlin H; Zamanian RT; de Jesus Perez VA
ERJ Open Res; 2019 Oct; 5(4):. PubMed ID: 31637253
[TBL] [Abstract][Full Text] [Related]
9. Epidemiology of Parkinson's disease.
Tanner CM
Neurol Clin; 1992 May; 10(2):317-29. PubMed ID: 1584176
[TBL] [Abstract][Full Text] [Related]
10. Hospital-treated infections and subsequent Parkinson's disease risk: a register-based sibling comparison study.
Vingeliene S; Hiyoshi A; Lentjes MAH; Brummer RJ; Fall K; Montgomery S
Brain Commun; 2024; 6(2):fcae098. PubMed ID: 38562309
[TBL] [Abstract][Full Text] [Related]
11. Predict the prevalence and incidence of Parkinson's disease using fractal interpolation-LSTM model.
Dai Z; Liu S; Liu C
Chaos; 2024 May; 34(5):. PubMed ID: 38717400
[TBL] [Abstract][Full Text] [Related]
12. Functional comorbidity in Parkinson disease: A window of opportunity.
Pareés I; Kurtis MM
Parkinsonism Relat Disord; 2024 Jan; 118():105937. PubMed ID: 38087736
[No Abstract] [Full Text] [Related]
13. A Response to the Paal et al. Rejoinder: Religiosity and Risk of Parkinson's Disease in England and the USA.
Koenig HG
J Relig Health; 2023 Dec; 62(6):4215-4221. PubMed ID: 36607566
[TBL] [Abstract][Full Text] [Related]
14. Addressing the "Replication Crisis" in the Field of Parkinson's Disease.
Albanese F; Bloem BR; Kalia LV
J Parkinsons Dis; 2023; 13(6):849-850. PubMed ID: 37694309
[No Abstract] [Full Text] [Related]
15. The elephant in the room: critical reflections on mortality rates among individuals with Parkinson's disease.
Dommershuijsen LJ; Darweesh SKL; Ben-Shlomo Y; Kluger BM; Bloem BR
NPJ Parkinsons Dis; 2023 Oct; 9(1):145. PubMed ID: 37857675
[TBL] [Abstract][Full Text] [Related]
16. Methamphetamine/amphetamine abuse and risk of Parkinson's disease in Utah: a population-based assessment.
Curtin K; Fleckenstein AE; Robison RJ; Crookston MJ; Smith KR; Hanson GR
Drug Alcohol Depend; 2015 Jan; 146():30-8. PubMed ID: 25479916
[TBL] [Abstract][Full Text] [Related]
17. Methamphetamine self-administration results in persistent dopaminergic pathology: implications for Parkinson's disease risk and reward-seeking.
Kousik SM; Carvey PM; Napier TC
Eur J Neurosci; 2014 Aug; 40(4):2707-14. PubMed ID: 24890790
[TBL] [Abstract][Full Text] [Related]
18. Increased risk of Parkinson's disease in individuals hospitalized with conditions related to the use of methamphetamine or other amphetamine-type drugs.
Callaghan RC; Cunningham JK; Sykes J; Kish SJ
Drug Alcohol Depend; 2012 Jan; 120(1-3):35-40. PubMed ID: 21794992
[TBL] [Abstract][Full Text] [Related]
19. Brain dopamine neurone 'damage': methamphetamine users vs. Parkinson's disease - a critical assessment of the evidence.
Kish SJ; Boileau I; Callaghan RC; Tong J
Eur J Neurosci; 2017 Jan; 45(1):58-66. PubMed ID: 27519465
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
